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Introduction
The introduction of stereotactic body radiotherapy (SBRT) 
has shifted the paradigm in the management of solid 
malignancies by enabling the delivery of highly conformal 
and targeted high-dose hypofractionated radiotherapy with 
excellent local control rates and minimal toxicities in the 
appropriately selected patient population (1). Although 
this technique has been used for intracranial irradiation 
(“radiosurgery”) for many years, its use in extracranial 
sites was initially limited by the lack of good quality image 
guided tumour localization/delivery and the ability to 
deliver highly conformal radiotherapy without damaging 
normal tissues. This changed with the advent of intensity-
modulated radiotherapy (IMRT), the use of CT/MRI for 
radiotherapy planning and treatment verification, as well as 
motion management.
SBRT is increasingly used in the management of 
unresectable liver metastases and hepatocellular carcinoma 
(HCC) (2-5) as it allows the delivery of ablative radiation 
doses with limited toxicities. Typically, a total of 30–60 Gy 
is delivered over 3–6 fractions using highly conformal non-
coplanar beams or arc therapy. The prescribed radiation 
dose is dependent on a multitude of patient and tumour 
factors (e.g., liver function, number of lesions) as well as risk 
of normal tissue toxicities. Tumour and liver appearances 
after SBRT may differ from conventionally fractionated 
radiotherapy due to the potentially different radiobiological 
effects on the tumour and normal tissues (6). Most of these 
radiobiological changes were also evaluated in preclinical 
models and uncertainty exists regarding the extrapolation 
of the preclinical dose fractionations used to the clinical 
setting due to the different doses used, and the biology 
of murine and human models. Hence, we will review the 
histopathological and imaging changes that occur following 
liver SBRT, which may be informative in improving our 
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post-treatment image surveillance programme and our 
ability to distinguish normal tumour response from disease 
progression.
Histopathological changes
Understanding the underlying biological and histological 
changes is important to allow interpretation of the changes 
seen on various imaging methods. Most of the evidence 
for the underlying histopathological radiation-induced 
changes has been derived from conventionally fractionated 
radiotherapy in non-cirrhotic liver. These features include 
hyperaemia, central vascular congestion with fibrin 
deposition and subsequent collagen formation as well as 
hepatic cell loss, known as veno-occlusive disease (VOD) 
(7-9). These changes tend to spare the larger veins and are 
typically observed between 1–4 months after radiation (7). In 
most cases, liver hyperaemia and hepatic cell atrophy tend 
to resolve after 4 months with some residual architectural 
lobular distortion (7,9).
Olsen et al. evaluated the histological changes in two 
patients who underwent surgical metastasectomy at 2 and 
8 months after liver SBRT (10). Both patients received 
60 Gy in 3 fractions. Despite the 6 months interval between 
the two specimens, three distinct zones of radiation induced 
changes were identified on both specimens. The central 
zone (zone I) contained central necrosis with fibrosis and 
scattered macrophages. Zone II was the capillary-rich 
repopulation zone with areas of fibrosis and granulation 
tissue, surrounded by regenerating hepatocytes. The outer 
zone III showed characteristics of VOD with central vein 
occlusion and marked sinusoidal congestion. There was a 
clear demarcation between irradiated and non-irradiated 
liver. Bile ducts were spared in all three zones. At 8 months, 
there was complete central vein obliteration by collagen 
fibers in zone III with less congestion and atrophy of the 
liver cell plates compared to that observed at 2 months.
Focal liver reaction (FLR)
Several imaging studies have reported the morphological 
and physiological changes observed in the immediate 
surrounding liver parenchyma receiving non-ablative 
radiation dose, known as FLR. Overall, normal liver volume 
decreased following liver SBRT (10). A median normal liver 
volume reduction of 18% (13–33%) was found at 2–6 months 
after SBRT in 15 patients with liver metastases (10). In 
a separate study using [18F]Fluorodeoxyglucose positron 
emission tomography (FDG PET/CT), there was an 
average 20% reduction of liver volume at 3–6 months after 
SBRT for liver metastases. Although regeneration occurred 
after 12 months, the liver volume remained 10% less than 
baseline (11).
In addition, a difference in the irradiated and non-
irradiated liver density has been observed after SBRT. 
Generally, a decrease in computed tomography (CT) 
density of 7–10 Hounsfield units (HU) between irradiated 
and non-irradiated liver is considered significant (12-14). 
The SBRT dose associated with a significant reduction in 
CT density was estimated to be between 30 to 35 Gy in 
3–5 fractions (13,15,16) although a lower threshold dose 
had also been suggested (median calculated threshold dose 
13.7 Gy in a single fraction; range, 8.9–19.2) (12). There 
is also a suggestion that an inverse relationship between 
SBRT dose and post-treatment normal liver CT density 
exists (13). However, there is no conclusive evidence that 
FLR observed after SBRT is related to the development of 
radiation-induced liver disease (RILD).
Yamasaki et al. first reported CT changes in 31 patients 
with HCCs, cholangiocarcinomas and liver metastases 
treated with high-dose fractionated conformal radiotherapy 
(48–73 Gy in 1.50–1.65 Gy twice daily fractions) (17). They 
found that the treated volumes adjacent to the tumours 
became hypodense on contrast-enhanced CT in 74% of 
the patients at 1–4 months post-treatment. In contrast, in 
the two patients with fatty infiltration, the treated volume 
showed increased density compared to the untreated liver. 
These changes did not correlate with the development of 
radiation hepatitis. Subsequent liver atrophy was observed 
in four patients, hypertrophy of uninvolved liver in another 
four patients and both effects were found in eight patients.
Herfarth et al. described three types of FLR in 36 
patients (1 HCC, 3 cholangiocarcinomas, 32 metastases) 
who were treated with single fraction SBRT (median dose 
22 Gy; range, 16–24) (12). Median follow-up for this cohort 
was 8.3 months (range, 1.3–17.9 months) after SBRT. 
Hypodense liver reaction was found in 58% of follow-up 
unenhanced CT scans compared to non-irradiated liver 
with a median density difference of −15 HU (range, −10 
to −30 HU). However, a third of scans showed no density 
difference between irradiated and non-irradiated liver. The 
authors classified the FLR changes into three types based on 
the density observed in the portal-venous and delayed phase 
scans: hypodense/isodense (Type 1), hypodense/hyperdense 
(Type 2) and isodense or hyperdense/hyperdense (Type 3). 
The median time to development of FLR was 1.8 months 
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(range, 1.2–4.6) and more than half (64%) of the patients 
developed type 1 reactions at the first occurrence. However, 
there was a shift to type 2 and 3 reactions at subsequent 
follow-up. The volume of FLR decreased at 2–4 months 
compared to the initial reaction volume (median 40%; 
range, 17–94%). In the previous study by Olsen et al., a 
comparison was made between the radiological Herfarth 
Type 1 and 2 reactions, and the corresponding pathological 
findings (10). They showed that the hypodensity in the 
portal-venous phase observed in Type 1 reaction was 
associated with tissue congestion and occlusion of small 
veins resulting in decreased perfusion, hence contrast 
inflow. In contrast, the hyperdensity observed in Type 2 
reaction was hypothesised to be secondary to progressive 
fibrin deposition and occlusion of the central veins causing 
stasis and pooling with reduced contrast clearance.
In a separate study by Sanuki-Fujimoto et al., three 
classifications of FLR following SBRT (30–40 Gy in 5 
fractions) for HCC in a background of cirrhosis were 
described (18). In this study, transarterial chemoembolization 
(TACE) was performed prior to SBRT. Most of the 
patients had Child-Pugh A cirrhosis. The group identified 
three FLR density patterns based on the pre-contrast, 
arterial and portal-venous phase scans: isodense/isodense/
isodense (Type A), hypodense/isodense/isodense (Type 
B) and hypodense/isodense or hyperdense/hyperdense 
(Type C). These changes occurred at a median of 3 months 
(range, 1–6 months) after SBRT. When Type A and B 
reactions were grouped as “unenhanced” as opposed to the 
“enhanced” Type C reaction, the authors found that livers 
with preserved function tend to be well enhanced in the 
delayed phase.
These observations were supported by another study by 
Kimura et al. which evaluated the changes in dynamic CT 
after SBRT (48 Gy in 4 fractions) for HCC in patients with 
Child-Pugh A and B liver cirrhosis (19). The majority of 
patients also underwent TACE prior to SBRT. Dynamic 
CT was performed in non-contrast, arterial, portal and 
venous phases. The CT density changes were classified 
into three types: Type 1—hyperdensity in all enhanced 
phases, Type 2—hypodensity in arterial and portal phases 
and Type 3—isodensity in all enhanced phases. This study 
found that half of Type 2 and 3 reactions changed to Type 
1, particularly in Child-Pugh A patients. In contrast, Type 
2 and 3 reactions remained unchanged in Child-Pugh B 
patients.
A further study also evaluated the contrast-enhancement 
changes in the adjacent irradiated normal liver after SBRT 
for HCC (14). Most patients (69%) were treated with SBRT 
alone whereas the remaining patients were treated with 
SBRT and TACE. Pre-contrast, arterial, portal and delayed 
CT phase images were acquired before, at one, three and 
six months post-treatment. The irradiated liver showed 
hypoattenuation compared to non-irradiated liver on non-
contrast images in 26% of patients at one month which 
increased to 79% at 6 months. In contrast, hypervascularity 
on the arterial phase was seen in 12% of patients at one 
month which increased to 54% at 6 months. There was 
little contrast washout on the delayed phase: 2% at 1 month 
and 0% at 6 months. These contrast enhancement changes 
were similar between those treated with SBRT alone, and 
combination of SBRT and TACE.
It is difficult to directly compare these studies due to 
several key differences such as the different types of liver 
tumours, treatment received, timing of assessment, CT 
imaging phases evaluated and contrast administration. 
Nonetheless, these studies showed that there was a 
significant change in the irradiated normal liver density 
compared to non-irradiated liver which tend to resolve 
over time (Figures 1,2). Overall, Herfarth Type 1 and 2, 
Sanuki-Fujimoto Type A and B and Kimura Type 2 and 3 
appearances were of the “unenhanced” pattern which was 
more prevalent in those with impaired liver function (Child-
Pugh B). Both studies by Sanuki-Fujimoto et al. and Kimura 
et al. showed that Child-Pugh score was a significant factor 
associated with the types of imaging changes observed 
(18,19). However, only Kimura et al. showed that non-type 
3 changes were associated with higher risk of adverse events 
(P=0.003) on univariate analysis but lost its significance in 
multivariate analysis.
Tumour response
Tumour response following SBRT is often heralded by 
a reduction in tumour enhancement on CT or magnetic 
resonance imaging (MRI) particularly in the first four 
months post-treatment and is usually followed by a 
decrease in overall tumour volume (20). Treated tumours 
typically show lower density compared to the adjacent liver 
parenchyma. In the study by Herfarth et al., tumour volume 
of controlled tumours decreased to a median of 27% (range 
0–74%) of the baseline volume. In the portal-venous phase, 
controlled tumours also showed a lower density than the 
radiation reaction [median difference against non-irradiated 
liver –64 HU (range, −15 to −100 HU); median difference 
against irradiated liver −50 HU (range, −14 to −115 HU)]. 
Yip et al. Imaging assessment after liver SBRT
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A
C
B
D
Figure 1 Radiotherapy plan showing the treated liver encompassed by 30 Gy in a patient with Child-Pugh A cirrhosis who was previously 
treated with TACE for a segment 4 HCC and subsequently had SBRT (40 Gy in 5 fractions) to the tumour thrombi (A,B), and CT liver 
in the portal-venous phase at 2 months after SBRT showing the FLR which corresponded to the area which received 30 Gy (C,D). TACE, 
transarterial chemoembolization; HCC, hepatocellular carcinoma; SBRT, stereotactic body radiotherapy; FLR, focal liver reaction.
Figure 2 MRI liver with gadoxetic acid showing a segment 5 liver metastasis from nasopharyngeal cancer with focal liver reaction and no 
evidence of tumour recurrence. (A) Baseline pre-contrast T1-weighted MRI; (B) baseline post-contrast T1-weighted MRI showing faint 
peripheral enhancement after chemotherapy (white arrow); (C) post-contrast T1-weighted MRI at 5 months post-SBRT showing a hypointense 
and non-enhancing lesion corresponding to the (D) treated lesion covered by the 50 Gy isodose line on the planning CT; and (E) smaller 
hypointense and non-enhancing lesion at 12 months post-SBRT. MRI, magnetic resonance imaging; SBRT, stereotactic body radiotherapy.
A
D
B
E
C
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Furthermore, blood vessels were not compressed or 
displaced by benign radiation reaction (12). The percentage 
of intratumoral necrosis was shown to be greater than the 
percentage of unidimensional size reduction in treated 
tumours up to 12 months post-SBRT (21). In addition, a 
halo of delayed enhancement can be observed in the liver 
parenchyma adjacent to the tumour, likely secondary to 
fibrosis (20). These characteristics are observed in primary 
liver HCC, metastases and cholangiocarcinomas treated 
with SBRT.
Separate imaging assessment criteria have been proposed 
for HCC such as the modified RECIST (mRECIST) and 
EASL methods which take into account tumour necrosis 
after local therapy (22,23). These criteria are used for 
both CT and MRI assessments. Both the mRECIST 
and EASL criteria measure the diameter of the viable 
arterially enhancing tumour component, rather than the 
whole tumour volume which includes the necrotic or non-
enhancing components. The key difference between the two 
criteria is that the mRECIST method uses unidimensional 
measurement as opposed to the EASL method which 
uses product of bidimensional diameters. Nonetheless, 
the two criteria showed good concordance and has good 
prognostic value in HCC treated with locoregional 
therapy (24). The percentage of tumour necrosis has been 
shown to increase up to 12 months in controlled primary 
liver tumours treated with SBRT (21). Using these criteria, 
more radiological complete responders are identified 
compared to size-based evaluation in the portal-venous 
phase as per RECIST 1.1 (21). Nonetheless, RECIST 1.1 
should still be considered in non-enhancing tumours or 
those with atypical enhancement. Another caveat is that 
these criteria have only been evaluated in HCC treated with 
non-radiotherapy modalities. Whether these are applicable 
to liver metastases and/or HCC treated with SBRT is still 
uncertain.
The development of lobulated enhancement on CT/
MRI after SBRT is associated with local relapse in liver 
metastases (25,26). A thick (>1 mm) peripheral enhancement 
with at least three lobulations was found to have a sensitivity 
of 89%, specificity of 100%, positive predictive value of 
100%, negative predictive value of 95% and accuracy of 
97% in predicting local disease progression. Lobulated 
enhancement also preceded size-based progression in half 
of the cases with confirmed local progression (median delay 
3.2 months). The 1-year progression-free survival (PFS) was 
higher in lesions without lobulated enhancement (HR 0.80; 
95% CI: 0.65–0.89) compared to lesions with lobulated 
enhancement (HR 0.69; 95% CI: 0.54–0.80; P<0.001). 
This pattern of enhancement can be reliably identified 
between different observers with a concordance rate of 
98% (26). The same group proposed a combined response 
criteria incorporating RECIST 1.1, necrosis and lobulated 
enhancement characteristics for liver metastases treated 
with SBRT (25). Using the combined criteria, 18% of 
patients were classified as complete responders as compared 
to 4% using the RECIST criteria. Two progressive diseases 
and two partial responses as determined by RECIST were 
classified as complete responses using the combined criteria.
Magnetic resonance imaging including diffusion-
weighted (DW) imaging is increasingly used in the 
diagnosis and follow-up of liver tumours. DW-MRI and its 
quantitative parameter, the apparent diffusion coefficient 
(ADC) measure the rate of diffusion (Brownian motion) of 
water molecules within a tissue which can be restricted by 
cellular structures such as cell membranes, and thus could 
be a surrogate measurement for cellularity (27). Areas of 
high cellularity with resultant restricted diffusion show low 
ADC values compared to areas with low cellularity which 
gives relatively high ADC values. 
In a preliminary study by Eccles et al., eleven patients 
(4 HCCs, 5 liver metastases and 2 cholangiocarcinomas) 
who were treated with SBRT (28.8–54 Gy in 6 fractions) 
underwent DW-MRI before treatment, week 1 and 
week 2 of radiotherapy and at 1 month post-SBRT (28). 
The authors found that the mean ADC of tumours 
increased significantly at week 1 (1,890×10−3 mm/s), week 
2 (1,911×10−3 mm/s) and 1 month (2,011×10−3 mm/s) 
compared to baseline (1,558×10−3 mm/s, P<0.0001). 
There was no significant change in the ADC values of the 
unirradiated liver receiving less than 8 Gy. In addition, 
there was no significant T2-weighted volumetric change 
during this interval.
In a separate study, the additional predictive value of 
DW-MRI in conjunction with conventional MRI using 
gadoxetic acid, a hepatocyte-specific contrast agent in 
diagnosing residual  viable HCC after  SBRT was 
evaluated (29). The mean interval between the end of 
treatment and follow-up MRI was 28 months (range, 
2.3–57.1 months). Overall, viable tumours showed 
hyperintensity in T2-weighted and arterial phase images 
(55%), hypointensity on portal (76%), 3-minute late 
(66%) and hepatobiliary phase (79%) images compared 
to irradiated liver (Figure 3). In contrast, 93% of viable 
tumours showed hyperintensity on DW images and 
hypointensity on ADC maps compared to irradiated liver 
Yip et al. Imaging assessment after liver SBRT
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(Figure 4). The diagnostic performance using the area under 
the curve (AUC) (0.798–0.805 vs. 0.936–0.957) and the 
interobserver agreement (Ƙ 0.450 vs. 0.748) were improved 
with the addition of DW-MRI to conventional MRI in the 
identification of viable tumours.
Yu et al. evaluated the role of DW-MRI in predicting 
local progression after SBRT for HCC compared to 
RECIST 1.1 and mRECIST in 48 patients (30). Follow-
up MRI was performed between 3 to 5 months after 
treatment. Similar to the previous study by Park et al., the 
authors found good interobserver agreement for region-
of-interest (ROI) volumes (intraclass correlations 0.84 
A
D
B
E
C
F
Figure 3 MRI liver with gadoxetic acid showing a recurrent segment 7 liver metastasis from colon cancer before (A-C) and 10 months 
after SBRT 50 Gy in 5 fractions (D-F). (A) Baseline pre-contrast T1-weighted MRI; (B) baseline post-contrast T1-weighted MRI showing 
tumour enhancement; (C) baseline T1-weighted hepatobiliary phase MRI showing lack of contrast uptake; (D) post-treatment pre-contrast 
T1-weighted MRI; (E) post-treatment post-contrast T1-weighted MRI showing peripheral and internal tumour enhancement; and (F) post-
treatment T1-weighted hepatobiliary phase MRI showing lack of contrast uptake in the tumour. SBRT, stereotactic body radiotherapy; 
MRI, magnetic resonance imaging.
Figure 4 DW-MRI of a segment 7 colorectal liver metastasis. (A) DW image (b50) showing high signal intensity and the corresponding (B) 
ADC parametric map showing some intratumoral restricted diffusion. DW, diffusion-weighted; MRI, magnetic resonance imaging; ADC, 
apparent diffusion coefficient.
A B
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and 0.85) and ADC values (intraclass correlations 0.87 
and 0.80) before and after radiotherapy. Both mRECIST 
(P<0.001) and ADC increment after SBRT (P=0.020) were 
significant prognostic factors for local progression-free 
survival (LPFS). The mRECIST criteria showed better 
diagnostic performance for LPFS (AUC 0.765) compared to 
RECIST 1.1 (AUC 0.635). However, the addition of ADC 
to RECIST 1.1 (AUC 0.745) had comparable diagnostic 
performance to mRECIST.
These results are promising but do not support the use of 
DW-MRI as a standard response assessment tool yet. Most 
of the studies included small number of patients with short 
follow-up, and used different acquisition parameters (e.g., 
b-values) and ROI definitions. In addition, tumour response 
was determined radiologically with limited follow-up, and 
without histological confirmation as it is often difficult to 
obtain repeat biopsy in these cases.
The use of [18F]FDG PET/CT is still limited in 
the staging and response assessment of liver tumours, 
particularly HCC. Nonetheless, a few studies have 
evaluated the use of [18F]FDG PET/CT in liver metastases 
treated with SBRT (11,31). The standardised uptake value 
(SUV) is commonly used to quantify FDG uptake within 
tumours. SUVmax is the highest value derived from a single 
voxel within a ROI. It was estimated that the time taken for 
the intratumoral SUVmax to decrease by 50% following liver 
SBRT was 2 months. The median post-treatment SUVmax 
in controlled tumour was 3.1 (range, 2.1–5.8) in one study 
which was reached at approximately 5 months post-SBRT. 
An intratumoral SUVmax greater than 6 after SBRT was 
considered as local failure if a prior post-SBRT SUVmax was 
less than 6 (11). 
Conclusions
In conclusion, it is common to observe imaging changes in 
the adjacent irradiated normal liver after SBRT which is 
likely related to the underlying histopathological changes 
with a transient decrease in liver volume, with these changes 
possibly affected by the patients’ underlying liver function. 
Intratumoral necrosis, lack of thick lobulated enhancement 
and subsequent tumour volume reduction are features 
suggestive of tumour response after SBRT. CT remains 
the standard method of assessing response post SBRT 
and we would recommend the use of multiphasic CT as 
the initial follow-up imaging assessment. Other imaging 
modalities such as DW-MRI and [18F]FDG PET/CT may 
be useful adjunct response assessment tools demonstrating 
a reduction in DWI signal, an increase in ADC and a 
decrease in SUV if further evaluation is required. Hence, 
liver-specific MRI or [18F]FDG PET/CT may be used if the 
initial CT findings are difficult to interpret (e.g., presence 
of fiducial markers) and/or to confirm the suspicion of 
tumour recurrence. We will suggest a 3-monthly imaging 
evaluation in the first year after SBRT followed by 
6-monthly evaluation thereafter.
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